The Insider Buying: Medtronic PLC (MDT) Director Buys $146,540.00 in Stock

The Insider Buying: Medtronic PLC (MDT) Director Buys $146,540.00 in Stock

Medtronic PLC (NYSE:MDT) Director James T. Lenehan acquired 2,000 shares of the stock in a transaction dated Wednesday, November 23rd. The shares were bought at an average cost of $73.27 per share, with a total value of $146,540.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Medtronic PLC (NYSE:MDT) opened at 75.52 on Monday. Medtronic PLC has a 12-month low of $71.03 and a 12-month high of $89.27. The company has a market capitalization of $104.36 billion, a PE ratio of 29.39 and a beta of 1.01. The stock has a 50 day moving average of $81.84 and a 200 day moving average of $84.68.

Medtronic PLC (NYSE:MDT) last issued its earnings results on Tuesday, November 22nd. The medical technology company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.01. Medtronic PLC had a net margin of 14.63% and a return on equity of 12.36%. The business had revenue of $7.35 billion for the quarter, compared to analyst estimates of $7.46 billion. During the same period in the previous year, the business earned $1.03 EPS. The firm’s revenue was up 4.1% on a year-over-year basis. On average, equities research analysts predict that Medtronic PLC will post $4.63 EPS for the current year.

Several hedge funds have recently modified their holdings of MDT. Proficio Capital Partners LLC raised its stake in shares of Medtronic PLC by 0.5% in the third quarter. Proficio Capital Partners LLC now owns 1,505 shares of the medical technology company’s stock valued at $130,000 after buying an additional 8 shares during the period. Hudock Capital Group LLC raised its stake in shares of Medtronic PLC by 0.5% in the second quarter. Hudock Capital Group LLC now owns 2,150 shares of the medical technology company’s stock valued at $186,000 after buying an additional 10 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Medtronic PLC by 0.3% in the third quarter. Jackson Grant Investment Advisers Inc. now owns 3,836 shares of the medical technology company’s stock valued at $331,000 after buying an additional 12 shares during the period. Parkside Financial Bank & Trust increased its position in shares of Medtronic PLC by 1.4% in the third quarter. Parkside Financial Bank & Trust now owns 2,105 shares of the medical technology company’s stock valued at $182,000 after buying an additional 30 shares in the last quarter. Finally, Moody National Bank Trust Division increased its position in shares of Medtronic PLC by 0.5% in the second quarter. Moody National Bank Trust Division now owns 6,953 shares of the medical technology company’s stock valued at $603,000 after buying an additional 35 shares in the last quarter. Institutional investors and hedge funds own 80.95% of the company’s stock.

MDT has been the subject of a number of research reports. Barclays PLC decreased their price target on shares of Medtronic PLC from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Wednesday, November 23rd. Oppenheimer Holdings Inc. decreased their price target on shares of Medtronic PLC from $94.00 to $84.00 and set an “outperform” rating for the company in a research report on Wednesday, November 23rd. Vetr cut shares of Medtronic PLC from a “strong-buy” rating to a “buy” rating and set a $91.28 price target for the company. in a research report on Monday, November 21st. Needham & Company LLC upped their price target on shares of Medtronic PLC from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, August 25th. Finally, Stifel Nicolaus decreased their price target on shares of Medtronic PLC from $91.00 to $81.00 and set a “hold” rating for the company in a research report on Wednesday, November 23rd. Seven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Medtronic PLC currently has an average rating of “Buy” and a consensus target price of $88.47.

Medtronic PLC Company Profile

Related posts

Leave a Comment